- Home
- XERS vs MDXG Comparison
XERS vs MDXG Comparison
Compare XERS & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XERS
- MDXG
- Stock Information
- Founded
- XERS 2005
- MDXG 2006
- Country
- XERS United States
- MDXG United States
- Employees
- XERS N/A
- MDXG N/A
- Industry
- XERS Biotechnology: Pharmaceutical Preparations
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- XERS Health Care
- MDXG Health Care
- Exchange
- XERS Nasdaq
- MDXG Nasdaq
- Market Cap
- XERS 752.7M
- MDXG 877.4M
- IPO Year
- XERS 2018
- MDXG N/A
- Fundamental
- Price
- XERS $5.11
- MDXG $6.67
- Analyst Decision
- XERS Strong Buy
- MDXG Strong Buy
- Analyst Count
- XERS 6
- MDXG 2
- Target Price
- XERS $6.25
- MDXG $12.50
- AVG Volume (30 Days)
- XERS 2.0M
- MDXG 771.8K
- Earning Date
- XERS 08-07-2025
- MDXG 07-30-2025
- Dividend Yield
- XERS N/A
- MDXG N/A
- EPS Growth
- XERS N/A
- MDXG N/A
- EPS
- XERS N/A
- MDXG 0.27
- Revenue
- XERS $222,551,000.00
- MDXG $352,375,000.00
- Revenue This Year
- XERS $35.03
- MDXG $9.55
- Revenue Next Year
- XERS $18.31
- MDXG $11.43
- P/E Ratio
- XERS N/A
- MDXG $25.11
- Revenue Growth
- XERS 29.88
- MDXG 5.34
- 52 Week Low
- XERS $2.10
- MDXG $5.47
- 52 Week High
- XERS $6.07
- MDXG $10.14
- Technical
- Relative Strength Index (RSI)
- XERS 61.48
- MDXG 57.60
- Support Level
- XERS $4.62
- MDXG $5.86
- Resistance Level
- XERS $5.39
- MDXG $7.05
- Average True Range (ATR)
- XERS 0.21
- MDXG 0.24
- MACD
- XERS 0.07
- MDXG 0.11
- Stochastic Oscillator
- XERS 71.72
- MDXG 69.20
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.